Michael G. Kaplitt, M.D., Ph.D.

Neurological Surgery
Michael Kaplitt

Michael Kaplitt, PhD, MD specializes in neurosurgical treatment of movement disorders, including Parkinson's disease, essential tremor and dystonia, using various surgical approaches including deep brain stimulation. He also specializes in surgery for intractable pain and spasticity, implanting devices such as spinal cord stimulators and spinal infusion pumps. He is also an expert in the treatment of trigeminal neuralgia and hydrocephalus, and perfroms general neurosurgery as well. He works with a team of specialists, including neurologists, neurophysiologists, neuropsychologists, brain imaging experts, physiatrists/therapists, and pain management specialists to provide superior care in all of these areas before, during and after surgery. Dr. Kaplitt is also an internationally recognized expert in gene therapy and molecular neurobiology, and he is a leading figure in the development of new technologies for improving or restoring brain function.

Michael Kaplitt graduated Magna Cum Laude from Princeton University in 1987 with a degree in Molecular Biology and Russian Studies. He enrolled in the Tri-Institutional M.D.-Ph.D. Program and received his Ph.D. in Molecular Neurobiology in 1993 from The Rockefeller University and his M.D. in 1995 from Cornell Medical College. Following his Neurosurgery residency and chief residency at Cornell, he completed a fellowship in Stereotactic and Functional Neurosurgery with Dr. Andres Lozano at the University of Toronto prior to joining our staff as Assistant Professor of Neurological Surgery in July 2001.

His clinical activities focus upon using minimally invasive, stereotactic techniques for the treatment of functional disorders such as Parkinson's disease, essential tremor and epilepsy. He also uses surgical methods to implant devices such as spinal cord stimulators and opiate pumps to treat complex pain, and he is also an expert in the treatment of trigeminal neuralgia and hydrocephalus. Dr. Kaplitt has pioneered the use of gene therapy in the brain. He has published over 40 papers and has edited two books on this subject. He recently completed the first clinical trial of gene therapy for Parkinson's Disease for FDA approval, and his laboratory is actively researching mechanisms of cell death in diseases such as Parkinson's and Huntington's. Dr. Kaplitt is the recipient of numerous awards, including the Young Investigator Award from the American Society for Gene Therapy and he was named to Crain's 40 under 40 list for 2004.

He currently serves on the editorial boards of several journals, and is Editor of the World Society for Stereotactic and Functional Neurosurgery Web Site. He is also a member of the Weill Cornell Medical School Committee on Admissions. He is also Adjunct Assistant Professor at The Rockefeller University and Clinical Assistant Surgeon at Memorial Sloan-Kettering Cancer Center.

~~~

Dr. Kaplitt sees patients at:
1305 York Avenue (at 70th Street)
Brain and Spine Center, 9th Floor
New York, NY 10065

~~~

Dr. Kaplitt in the News
Promising Results from First Gene Therapy Clinical Trial for Parkinson's Disease Reported in The Lancet

Dr. Kaplitt's Book
Gene Therapy of the Central Nervous System: From Bench to Bedside

Press Highlight
Crain's New York Business' 40 Under 40 Feature of Dr. Kaplitt

Patient Guide
Including how to make and prepare for an appointment, maps and directions, and registration/history forms

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [HMO]
  • AETNA [PPO]
  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]

Publications

BOOKS AND BOOK CHAPTERS

 

1. Kaplitt MG and Loewy AD, Editors. (1995) Viral Vectors: Gene Therapy and Neuroscience Applications. San Diego, CA: Academic Press.

 

2. Mobbs CV, Kaplitt MG and Pfaff DW (1997) #147;HIP-70/GRP58/Erp61/PLC-a/CPT: A single gene product and member of the protein disulfide isomerase gene family with thiol oxidoreductase activity subject to neuroendocrine regulation#148;, in Prolyl Hydroxylase, Protein Disulfide Isomerase and Other Structurally Related Proteins (Guzman N, ed.) New York: Marcel Dekker, Inc.

 

3. Kaplitt MG and Loewy AD (1999) #147;Viral Vectors#148;, in Fundamental Neuroscience (Bloom, et. al. eds) San Diego, CA: Academic Press.

 

4. Kaplitt MG and Lozano, AM (2001) Surgical drug delivery for neurodegenerative diseases. Clin Neurosurg 48:127-144.

5. Kaplitt MG, Hutchinson W and Lozano, AM (2001) #147;Target Localization in Movement Disorder Surgery#148;, in Contemporary Clinical Neurology: Surgical Treatment of Parkinson#146;s Disease and Other Movement Disorders (Tarsy, D. et. al., eds.) Totowa, NJ: Humana Press.

 

6. Kaplitt MG, Dostrovsky J, Hutchinson W and Lozano AM #147;Microelectrode Recording in Functional Neurosurgery#148; in Neurosurgery (Wilkins, RH and Rengachary, SS, eds.). New York: McGraw-Hill. In press.

 

7. Kaplitt MG and Loewy AD (2003) #147;Viral Vectors#148;, in Fundamental Neuroscience, 2nd ed. (Bloom, et. al. eds) San Diego, CA: Academic Press.

 

8. Kaplitt MG, Rezai AR, Lozano A and Tasker R (2004) #147;Deep Brain Stimulation for Chronic Pain#148; in Youmans Neurological Surgery, 5th Edition (H.R. Winn, ed.). Philadelphia: Elsevier.

 

9. Kaplitt MG and During MJ, Editors (2005) Gene Therapy in the Brain: From Bench to Bedside. London: Elsevier.

 

PEER-REVIEWED PUBLICATIONS

 

1. Mobbs CV, Kaplitt MG, Kow L-M, Pfaff DW (1991) PLC-a: A common mediator of the actionof estrogen and other hormones? Mol. Cell. Endocrinol. 80:C187-C191.

 

2. Kaplitt MG, Pfaus JG, Kleopoulos SP, Hanlon BA, Rabkin SD, Pfaff DW (1991) Expression of a functional foreign gene in adult mammalian brain following in vivo transfer via a herpes simplex virus type 1 defective viral vector. Mol. Cell. Neurosci. 2:320-330.

 

3. Kaplitt MG, Rabkin SD, Pfaff DW (1992) Molecular alterations in nerve cells: Direct manipulation and physiologic mediation. Curr. Top. Neuroendocrinol. 11:169-191.

 

4. Kaplitt MG, Kleopoulos SP, Pfaff DW, Mobbs CV. (1993) Estrogen induces HIP-70/PLC-amessenger RNA in the uterus and ventromedial hypothalamus. Endocrinology 133:99-104.

 

5. Brooks PJ, Kaplitt MG, Kleopoulos SP, Funabashi T, Mobbs CV, Pfaff DW. (1993) Sensitive detection of low abundance RNAs by in situ hybridization using single-stranded DNA probes produced by amplified primer extension labeling. J. Histochem. Cytochem. 41:1761-1766.

 

6. Kaplitt MG, Kwong AD, Kleopoulos SP, Mobbs CV, Rabkin SD, Pfaff DW. (1994) Preproenkephalin promoter yields region-specific and long-term expression in adult rat brain following in vivo transfer via a defective herpes simplex viral vector. Proc. Natl. Acad. Sci. USA, 91:8979-8983.

 

7. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, OMalley K, During MJ (1994) Long-term expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nature Gen. 8:148-154.

 

8. Kaplitt MG, Tjuvajev J, Leib DA, Berk J, Rabkin SD, Posner JB, Pfaff DW, Blasberg RG. (1994) Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats. J. Neuro-oncology 19:137-142.

 

9. Verhaagen J, Hermens W, Oestricher B, Rabkin SD, Pfaff DW, Gispen WH, Kaplitt MG (1994) Expression of B-50 (GAP43) via a defective herpes simplex virus vector yields morphological changes in cultured non-neuronal cells. Mol. Brain Res. 26:26-36

 

10. Dutt A, Kaplitt MG, Kow LM, Pfaff DW. (1994) Prolactin, CNS and Behavior, a critical review. Neuroendocrinol. 59:413-419.

 

11. Yin J, Kaplitt MG, Pfaff DW (1994) In situ PCR and in vivo detection of foreign gene expression in rat brain. Cell Vision 1:58-59.

 

12. Eizenberg O, Kaplitt MG, Eitan S, Pfaff DW, Hirschberg DL, Schwartz M. (1994) Linear dimeric interleukin-2 obtained by the use of a defective viral vector: conformation-activity relationship. Mol. Brain Res. 26:156-162.

 

13. Wood MJA, Byrnes A, Kaplitt MG, Pfaff DW, Rabkin SD, Charlton HD (1994) Specific pattern of defective HSV1 gene transfer in the adult central nervous system: Implications for gene targeting. Exp. Neurol. 130:127-140.

 

14. Rosenfeld MR, Meneses PM, Dalmau J, Drobnjak M, Cordon-Cardo C, Kaplitt MG (1995) Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology 45:1533-1539.

 

15. Tjuvajev J, Gansbacher B, Desai R, Beattie B, Kaplitt MG, Matei C, Koutcher J, Gilboa E, Blasberg R. (1995) RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55:1902-1910.

 

16. Holtmaat AJ, Hermens WT, Oestreicher AB, Gispen WH, Kaplitt MG, Verhaagen J. (1996) Efficient adenoviral vector directed expression of a foreign gene to neurons and sustentacular cells in the mouse olfactory neuroepithelium. Mol. Brain Res. 41:148-156.

 

17. Kaplitt MG, Gouras GK, Makimura H, Jovanovic J, Sweeney D, Greengard P, Relkin NR, Gandy S. (1996) Apolipoprotein E, A beta-amyloid, and the molecular pathology of Alzheimer's disease. Therapeutic implications. Ann. N.Y. Acad. Sci. 802: 42-9.

 

18.Kaplitt MG, Xiao X, Samulski RJ, Li R, Ojamaa K, Klein IL, Makimura H, Kaplitt MJ, Strumpf RK, Diethrich EB (1996) Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann. Thoracic Surg. 62(6): 1669-76.

 

19. Vogt L, Giger RJ, Ziegler U, Kunz B, Buchstaller A, Hermens W, Kaplitt MG, Rosenfeld MR, Pfaff DW, Verhagen J, Sonderegger P (1996) Continuous renewal of the axonal pathway sensor apparatus by insertion of new sensor molecules into the growth cone membrane. Current Biology 6(9): 1153-8.

 

20. Freese A, Stern M, Kaplitt MG, O'Connor WM, Abbey MV, O'Connor MJ, During MJ (1996) Prospects for gene therapy in Parkinson's disease. Movement Disorders 11:469-488.

 

21. Freese A, During MJ, Davidson BJ, Gennarelli TA, Kaplitt MG, Flamm ES, Snyder PJ (1996) Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release. J. Clin. Endocrinol. Metab. 81: 2401-4.

 

22. Freese A, Kaplitt MG, WM OC, Abbey M, Langer D, Leone P, MJ OC, During MJ (1997) Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy. Epilepsia 38:759-66.

 

23. Holtmaat AW, Hermens V, Sonnemans MAF, Giger RJ, Van Leeuwen FW, Kaplitt MG, Oestreicher AB, Gispen WH, Verhaagen J (1997) Adenoviral Vector-Mediated Expression of B-50/GAP-43 Induces Alterations in the Membrane Organization of Olfactory Axon Terminals In Vivo. J Neurosci 17:6575-86.

 

24. Kaplitt MG, Makimura H (1997) Defective viral vectors as agents for gene transfer in the nervous system. J Neurosci Methods 71:125-32.

 

25. O'Connor WM, Davidson BL, Kaplitt MG, Abbey MV, During MJ, Leone P, Langer D, MJ O'Conner and Freese A (1997) Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: prospects for gene therapy in epilepsy. Exp Neurol 148:167-78.

 

26. Rosenfeld MR, Bergman I, Schramm L, Griffin JA, Kaplitt MG, Meneses PI (1997). Adeno-associated viral vector gene transfer into leptomeningeal xenografts. J Neurooncol 34(2): 139-44.

 

27. Sugiyama A, Hattori S, Tanaka S, Isoda F, Kleopoulos S, Rosenfeld M, Kaplitt MG, Sekihara H, Mobbs C (1997) Defective adeno-associated viral-mediated transfection of insulin gene bydirect injection into liver parenchyma decreases blood glucose of diabetic mice. Horm Metab Res 29:599-603.

 

28. During MJ, Samulski RJ, Elsworth JD, Kaplitt MG, Leone P, Xiao X, Li J, Freese A, Taylor JR, Roth RH, Sladek JR, O'Malley KL, Redmond DE (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Therapy 5:820-827.

 

29. Kaplitt MG, Darakchiev BJ, During MJ (1998) Prospects for gene therapy in pediatric neurosurgery. Pediatr Neurosurg 28:3-14.

 

30. During MJ, Xu R, Young D, Kaplitt MG, Sherwin RS, Leone P (1998) Peroral gene therapy of lactose intolerance using an adeno-associated virus vector. Nat Med 4:1131-1135.

 

31. Yin J, Kaplitt MG, Kwong AD, Pfaff DW (1998) In situ PCR for in vivo detection of foreign genes transferred into rat brain. Brain Res 783:347-354.

 

32. Kanno H, Hattori S, Sato H, Murata H, Huang FH, Hayashi A, Suzuki N, Yamamoto I, Kawamoto S, Minami M, Miyatake S, Shuin T, Kaplitt MG (1999) Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-gamma. Cancer Gene Ther 6:147-154

 

33. Thomas DL, Shin S, Jiang BH, Vogel H, Ross MA, Kaplitt MG, Shenk TE, Javier RT (1999) Early region 1 transforming functions are dispensable for mammary tumorigenesis by human adenovirus type 9. J Virol 73:3071-3079

 

34. Bilsky MH, Downey RJ, Kaplitt MG, Elowitz EH, Rusch VW (2001) Tension pneumocephalus resulting from iatrogenic subarachnoid-pleural fistulae: report of three cases. Ann Thorac Surg 71:455-457.

 

35. During MJ, Kaplitt MG, Stern MB, Eidelberg D (2001) Subthalamic GAD gene transfer in Parkinson#146;s disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12:1589-1591.

 

36. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga D, Raniga S, Oshinsky M, During MJ (2002) Subthalamic GAD gene therapy in a Parkinson#146;s disease rat model. Science 298:425-429.

 

37. Moussatov S, Roberts J, Pfaff D and Kaplitt MG (2002) A cis-acting element that directs exclusively circular adeno-associated virus replication and packaging. J. Virol. 76:12792-12802.

 

38. Betchen S and Kaplitt MG (2003) Current and future surgical therapies for Parkinson#146;s Disease. Curr. Op. Neurol. 16:487-494.

 

39. Scott RE, Wu-Peng XS, Kaplitt MG, Pfaff DW (2003) Gene transfer and in vivo promoter analysis of the rat progesterone receptor using a herpes simplex virus viral vector. Mol. Brain Res. 114:91-100.

 

40. Hamani C, Saint-Cyr JA, Fraser J, Kaplitt MG, Lozano AM (2004) The subthalamic nucleus in the context of movement disorders. Brain 127:4-20.

 

41. Musatov S, Roberts J, Brooks AI, Pena J, Betchen S, Pfaff DW and Kaplitt MG (2004). The PTEN anti-oncogene negatively regulates the neuronal phenotype in PC12 cells. Proc. Natl. Acad. Sci. USA, 101:3627-3634.

 

42. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P, Souweidane M, Hosain S, Heier L, Ballon D, Dinner M, Wisniewski K, Kaplitt MG, Greenwald BM, Howell JD, Strybing K, Dyke J, Voss H (2004) Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gen. Ther. 15:1131-1154.

 

43. Arkin LM, Sondhi D, Worgall S, Suh LH, Hackett NR, Kaminsky SM, Hosain SA, Souweidane MM, Kaplitt MG, Dyke JP, Heier LA, Ballon DJ, Shungu DC, Wisniewski KE, Greenwald BM, Hollmann C, Crystal RG (2005) Confronting the issues of therapeutic misconception, enrollment decisions and personal motives in genetic medicine-based clinical research studies for fatal disorders. Hum. Gene Ther. 16:1028-1036.

 

44. Betchen S, Mousatov S, Roberts J, Pena J, Kaplitt MG (2005) PTEN inhibits adrenomedullin expression and function in glioma cells. J Neuroonc., In press.

 

45. Cooper L, Chan D, Roediger F, Shaffer B, Fraser J, Musatov S, Selesnick S, Kaplitt MG (2006) AAV-Mediated Delivery of the Caspase Inhibitor XIAP Protects Against Cisplatin Ototoxicity. Otology and Neurot., 27:484-490.

 

46. Musatov S, Chen W, Pfaff DW, Kaplitt MG, Ogawa S (2006) RNAi-mediated silencing of estrogen receptor a in the ventromedial nucleus of the hypothalamus abolishes female sexual behaviors. Proc. Natl. Acad. Sci. USA, 103:10456-10460.

 

47. Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D (2006) Network modulation in the treatment of Parkinson’s disease. Brain 129:2667-2678.

 

48. Musatov S, Chen W, Pfaff DW, Mobbs CV, Clegg D, Kaplitt MG, Ogawa S (2007) Silencing of estrogen receptor alpha in the ventromedial nucleus of the hypothalamus leads to a metabolic syndrome. Proc. Natl. Acad. Sci. USA104:2501-2506.

 

49. Emborg M, Carbon M, Holden JE, During MJ, Ma Y, Tang C, Moirano J, Fitzimmons H, Rotiberg BZ, Tuccar E, Roberts A, Kaplitt MG, Eidelberg D (2006) Subthalamic GAD Gene Therapy Changes Cortical Metabolism and Motor Function J Cereb. Blood Flow Metab. 27:501-509.

 

50. Chan D, Lieberman D, Mousatov S, Selesnick S, Kaplitt MG (2007) Protection against cisplatin-induced ototoxicity by AAV-mediated delivery of the X-linked inhibitor of apoptosis (XIAP) is not dependent on caspase inhibition. Otology and Neurot., 28:417-425.

 

51. Kaplitt MG, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor P, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and Tolerability of AAV-GAD Gene Therapy for Parkinson’s Disease: An open-label, phase I trial. Lancet, 369:2097-2105.

 

52. Wargall S, Kekatpure MV, Heier L, Ballon D, Dyke JP, Shungu D, Mao X, Kosofsky B, Kaplitt MG, Souweidane MM, Sondhi D, Hackett NR, Hollmann C, Crystal RG (2007) Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology, 69:521-35.

 

53. Kaplitt MG, Feigin A, Tang C, Lin T, Dhawan V, During MJ, Eidelberg, D. Modulation of Metabolic Brain Networks Following Subthalamic Gene Therapy for Parkinson’s Disease. Proc. Natl. Acad. Sci. USA, 104:19559-19564.

 

 

54. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, Dyke JP, Ballon D, Heier L, Greenwald BM, Christos P, Mazumdar M, Souweidane MM, Kaplitt MG, Crystal RG. (2008) Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA. Human Gene Ther 19:463-474.

 

55. Schultz K, von Esenwein SA, Hu M, Bennett AL, Kennedy RT, Musatov S, Toran-Allerand CD, Kaplitt MG, Young LJ, Becker JB. (2009) Viral Vector Mediated Over-Expression of Estrogen Receptor-a in Striatum Enhances the Estradiol-Induced Motor Activity in Female Rats and Estradiol Modulated GABA Release. J Neurosci, 29:1897-1903.

 

56. Liu W, Vives-Bauza C, Acin-Perez R, Yamamoto A, Tan Y, Li Y, Magrane J, Stavarache MA, Shaffer S, Chang S, Kaplitt MG, Huang XY, Beal MF, Manfredi G, Li C (2009) PINK1 Defect Causes Mitochondrial Dysfunction, Proteasomal Deficit and Alpha-Synuclein Aggregation in Cell Culture Models of Parkinson’s Disease. PLoS One 4:e4597.

57. Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt MG, Eidelberg D (2009) Assessing the Microlesion Effect of Subthalamic Deep Brain Stimulation Surgery with FDG PET. J Neurosurg 110:1278-1282. 

58. Johnson F and Kaplitt MG (2009) Novel Mitochondrial Substrates of Omi Indicate a New Regulatory Role in Neurodegenerative Disorders. PLoS One, In press.

59. Alexander B, Warner-Schmidt J, Eriksson T, Tamminga C, Ghose S, Arango-Llievano M, Vernov M, Stavarche M, Musatov S, Flajolet M, Svenningsson P, Greengard P, Kaplitt MG. Reversal of Depressed Behaviors by p11 Gene Therapy in the Nucleus Accumbens, Submitted.

60. Stavarche M, Souliopoulos E, Musatov S, Kaplitt MG. PTEN Mediates Striatal Dopamine Responses in Normal and Parkinsonian Mice. In preparation.

Honors and Awards

  •    1992 Albert Cass Traveling Fellowship
  •    1994 Saul R. Korey Award for Experimental Neurology, American Academy of Neurology
  •    Distinguished Housestaff Award, The New York Hospital-Cornell Medical Center
  •    Fellowship Award, Medical Research Council of Canada
  •    2002 Elsberg Fellowship, The New York Academy of Medicine
  •    2002 Ellison Foundation, New Scholar in Aging Research
  •    2004 New York Magazine, "Best Doctors in New York" feature
  •    2004 Crain's "40 Under 40" Award
  • 2005 American Society for Gene Therapy Young Investigator Award